## FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	(S)													
1. Name and Address of Reporting Person* PARKER H STEWART			2. Issuer Name and Ticker or Trading Symbol ONCOGENEX PHARMACEUTICALS, INC. [OGXI]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  _X_ Director 10% Owner Officer (give title below) Other (specify below)						
(Las 1522 217	1	(First) CE SE, SUITE 10		3. Date of 06/08/20		ransa	ction (Month	n/Day/Year)							
BOTHEI	LL. WA 98	(Street)		4. If Amer	ndment, D	ate O	riginal Filed	Month/Day/Ye	ar)	_X_	Form filed by	One Reporting	up Filing(Che g Person Reporting Perso		Line)
	City) (State) (Zip)			Table I - Non-Derivative Securities Acqu						quired,	lired, Disposed of, or Beneficially Owned				
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	any	n Date, if	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Owr Tran	ned Follownsaction(s)			6. Ownership Form:	Beneficial	
				(Month/L	Day/Year)		ode V		A) or (D) Pric	or In (I)			Ownership (Instr. 4)		
							conta	ns who res ined in this displays a	s form ar		required	to respon	d unless th ber.	ie	
							conta	ined in this	s form ar		required	to respon		ne	
	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if	4. Transact	5. Num of Deri Secu Acqu (A) C Disp	ber vative rities nired or osed	conta form o	ined in this displays a  posed of, or convertible ercisable and Date	Beneficia securities 1 7. Ti of Un Secu	y valid ally Ow )	required OMB co	to respon introl num	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Owners Form o Derivat Security Direct ( or Indir (s) (I)	Ownersl (Instr. 4) D) ect
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if	4. Transact	5. Num of Deri Secu Acqu (A) of	ber vative rities nired or osed 0)	quired, Dispos, options, of Expiration	ined in this displays a  posed of, or convertible ercisable and Date	Beneficia securities 1 7. Ti of Un Secu	y valid  ally Ow  tile and  nderlyin  rities	required OMB co	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported	of 10. Owners Form o Derivat Security Direct ( or Indir	hip of Indire f Benefici ive Ownersl (Instr. 4) ect
Derivative Security	Conversion or Exercise Price of Derivative	Date	3A. Deemed Execution Date, if	4. Transact	s, calls, wa f. 5. Num of Deri Secu Acqu (A) c Disp of (I (Inst 4, an	ber vative rities nired or osed 0)	quired, Dispos, options, of Expiration	ined in this displays a  posed of, or convertible crisiable and Date by/Year)	Beneficia securities i 7. Ti of U: Secu (Inst	y valid ally Ow ) tle and nderlyin rities r. 3 and	required OMB co	8. Price of Derivative Security	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction	of 10. Owners Form o Derivat Security Direct ( or Indir (s) (I)	hip of Indire f Benefici ive Ownersl (Instr. 4) ect

#### **Reporting Owners**

D (1 0 V (	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
PARKER H STEWART 1522 217TH PLACE SE SUITE 100 BOTHELL, WA 98021	X					

### **Signatures**

Sandra Thomson as attorney-in-fact for H. Stewart Parker	06/09/2010
Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The options shall vest in full on the earlier of June 8, 2011 or the date immediately prior to Oncogenex Pharmaceuticals, Inc.'s next annual meeting of

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.